Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacific
- Written by Reporters
SINGAPORE - Media OutReach - Mar 3, 2017 - Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine in oncology. Angsana Molecular & Diagnostics'...